BG Medicine Stock Spikes on Increased Reimbursement for Heart Disease Test

BG Medicine saw its stock value spike 37 percent Monday morning before settling back down after the company announced that Medicare and Medicaid will almost double reimbursement for the company’s diagnostic test for heart failure.
Boston Business Journal